Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

January 19, 2024

https://www.globenewswire.com/news-release/2023/12/18/2797734/0/en/Structure-Therapeutics-Provides-Comprehensive-GSBR-1290-Program-Update-Including-Clinically-Meaningful-Proof-of-Concept-Data-From-Phase-2a-Clinical-Study.html

GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug
in diabetes and 0% study discontinuation rate due to adverse events in obesity

Read more at globenewswire.com

Related news for (GPCR)

    NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.